Einstein International Journal Organization(EIJO)

Immunotherapy is one of the newer entities which is promising, at least can be very much helpful as an adjuvant therapy. This newer modality of the treatment in the field of cancer treatment may be the fourth pillar supporting surgery, chemotherapy, and radiotherapy. Careful selection of patient is the key for success of immunotherapy, which is based on patient’s immunological contexture.

Immunotherapies are disease management strategies that target or manipulate components of the immune system. Infectious diseases pose a significant threat to human health as evidenced by countries continuing to grapple with several emerging and re-emerging diseases

Novel and innovative therapeutic strategies are necessary to overcome the challenges typically faced by existing infectious disease prevention and control methods such as lack of adequate efficacy, drug toxicity, and the emergence of drug resistance.

As evidenced by recent developments and success of pharmaceuticals such as monoclonal antibodies (mAbs), immunotherapies already show abundant promise to overcome such limitations while also advancing the frontiers of medicine.

This review aimed to present the fundamental aspects of tumor immunity and immunotherapy, focused on various oral diseases.

1. "Immunotherapy Memorial Sloan Kettering Cancer Center". mskcc.org. Retrieved 2017-07-27.
2. Jump up to:  Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
3. Conforti L (February 2012). "The ion channel network in T lymphocytes, a target for immunotherapy". Clinical Immunology. 142 (2): 105–106. doi:10.1016/j.clim.2011.11.009. PMID 22189042.
4. Wang, S., Zimmermann, S., Parikh, K., Mansfield, A.S., & Adjei, A.A. (2019). Current diagnosis and management of small-cell lung cancer. Mayo Clinic Proceedings, 94(8), 1599–1622. https://doi.org/10.1016/j.mayocp.2019.01.034
5. Prettyman, J., Engel, L., Boldt-Houle, D.M., Atkinson, S., & Wilt, W. (2018). Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing, 39(2), 83–99. https://doi.org/10.7257/1053-816x .2019.39.2.83
6. Clarke, J.M., George, D.J., Lisi, S., & Salama, A.K.S. (2018). Immune checkpoint blockade: The new frontier in cancer treatment. Targeted Oncology, 13(1), 1–20. https://doi.org/ 10.1007/s11523-017-0549-7
7. Chalmers, A.W., Patel, S.B., & Akerley, W. (2018). Immunother-apy after chemoradiotherapy in stage III non-small cell lung cancer: A new standard of care? Journal of Thoracic Disease, 10(3), 1198–1200. https://doi.org/10.21037/jtd.2018.01.160
8. Bayer, V., Amaya, B., Baniewicz, D., Callahan, C., Marsh, L., & McCoy, A. S. (2017). Cancer immunotherapy: An evidence-based overview and implications for practice. Clinical Journal of Oncology Nursing, 21(2, Suppl.), 13–21. https://doi.org/10.1188/17.CJON.S2.13-211
9. Offner B.J., Rinke L. Immunotherapy assessment: Using a survey instrument to examine oncology nurses' confidence levels with administration and management. Clin. J. Oncol. Nurs. 2021;25(3):343-346. doi: 10.1188/21.CJON.343-346
10. Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman JH (January 2014). "Immunomodulatory drugs: oral and systemic adverse effects". Medicine Oral, Pathologic Oral y Cirugia Bucal. 19 (1): e24 – e31. doi: 10.4317 /med oral. 19087.  PMC 3909428. PMID 23986016.